Disease Overview：Glioma（GLM）
Glioblastoma and other gliomas are primary malignant brain tumors arising from glial cells—astrocytes, oligodendrocytes, or ependymal cells. Graded I–IV by the WHO classification, high-grade gliomas (especially GBM, WHO grade IV) are aggressive, infiltrative, and associated with poor prognosis due to blood-brain barrier limitations, tumor heterogeneity, and resistance to conventional therapies. Symptoms often include headaches, seizures, cognitive decline, or focal neurological deficits, necessitating multimodal management: maximal safe surgical resection followed by adjuvant radiotherapy and temozolomide chemotherapy. Emerging approaches—such as fluorescence-guided surgery (5-ALA), intraoperative MRI, awake craniotomy for functional mapping, and tumor-treating fields (TTFields)—are increasingly integrated into standardized protocols.
China offers distinct advantages in glioma care: leading neuro-oncology centers—like Beijing Tiantan Hospital and Shanghai Huashan Hospital—combine deep expertise in complex cranial oncology with state-of-the-art infrastructure, including 3T intraoperative MRI, robotic-assisted navigation, and next-generation sequencing for molecular profiling (IDH1/2, MGMT promoter methylation, 1p/19q codeletion). Clinical outcomes align with international benchmarks: 5-year survival for grade III gliomas exceeds 40%, and GBM median overall survival reaches 16–18 months with optimized multimodal therapy. Treatment costs in China are typically 40–60% lower than in the US or Western Europe—without compromising quality—making advanced neuro-oncology accessible without financial hardship.
As a dedicated medical tourism agency, we facilitate seamless international patient journeys: verifying hospital credentials, coordinating appointments with certified neurosurgeons and neuro-oncologists, providing itemized, transparent pricing, arranging visas and accommodation, and offering multilingual clinical support—from pre-arrival consultation through post-discharge follow-up.
Glioma: treatment in China helps patients compare specialist hospitals, initial assessment steps and estimated costs that may vary by city, institution and clinical condition.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Glioma (Neuro-Oncology)
Non-Surgical / Conservative / Medication Options
*Indicated for low-grade gliomas (WHO I–II), unresectable tumors, or palliative care.*
- •Corticosteroids (e.g., dexamethasone): Reduce peritumoral edema.
- •Antiepileptic Drugs (e.g., levetiracetam): Seizure prophylaxis/treatment.
- •Temozolomide (adjuvant chemo for grade III/IV): Oral alkylating agent.
- •Supportive Care Labs & Monitoring:
- MRI brain with contrast (q3mo for low-grade; q6–8wk for high-grade): $320–$410 - EEG (if seizure suspected): $85
Surgical / Procedural / Interventional Options
*Eligibility: KPS ≥70, no contraindications to craniotomy, tumor location permitting safe resection.*
- •Craniotomy + Gross Total Resection (GTR): Gold standard for accessible gliomas.
- Intraoperative neuromonitoring (SSEP/MEP): $380 - Intraoperative MRI (if available): +$1,100
- •Stereotactic Biopsy (for deep/inoperable lesions): Diagnostic confirmation only.
- •Preoperative Workup (mandatory):
- Functional MRI/fMRI + DTI tractography: $520 - Pre-anesthesia evaluation + ECG + chest X-ray: $135
Special / Complex Condition Options
- •Recurrent/Refactory Glioblastoma (GBM):
- Bevacizumab IV (4-week cycle): $1,950–$2,200/cycle
- •Pediatric Diffuse Midline Glioma (H3K27M-mutant):
- Clinical trial enrollment (including molecular profiling): $0–$1,200 (varies by sponsor coverage)
- •Elderly (>70 years) or Frail Patients:
- Palliative surgery (debulking only): $3,100–$4,000
Quick Selection Guide
- •Young adult (<45), fit, newly diagnosed GBM: Prioritize GTR + adjuvant temozolomide + TTFields — optimal survival benefit despite higher upfront cost ($12,500–$15,000 initial phase).
- •Elderly (>75) or severe comorbidities: Start with hypofractionated RT ± temozolomide — balances efficacy and tolerability ($5,000–$6,500 total).
- •Low-grade glioma (grade II), asymptomatic: Active surveillance + serial MRI — defers intervention; annual cost ~$1,800 (imaging + labs).
- •Limited budget (<$3,000): Biopsy + palliative temozolomide + steroids — confirms diagnosis and controls symptoms at lowest viable cost.
- •Recurrent GBM with prior resection: Bevacizumab + supportive care, avoiding repeat surgery unless mass effect is life-threatening.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Glioma Medical Vacation Packages
Curated transparent all-inclusive packages combining Glioma treatment with China top medical destinations:
